Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Incre

Original reporting
Published Nov 12, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SRTS
Bearish
high confidence
Mentioned
$SRTS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SRTSBearishMed
01

Why it matters

The earnings release underscores margin improvement but also revenue contraction, suggesting near‑term volatility.

02

Market read

Earnings miss for a micro‑cap med‑tech firm; likely short‑term downside pressure.

03

What to watch

International expansion and the 1,000th system milestone may provide longer‑term upside not reflected in the immediate earnings reaction.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Sensus Healthcare provides non‑invasive skin‑cancer treatment systems; the quarter saw a shift to lower‑priced models and loss of a major customer.

Company-level read

Ticker impact

$SRTSBearishHigh confidence
Context

Q3 2026 earnings released with revenue down 13% YoY, net loss widening and cash declining.

Expected impact

downward pressure as investors digest weaker revenue and expanding loss.

Evidence & confidence

Revenue fell to $6.0M from $6.9M, net loss widened to $1.5M, and cash fell to $12.9M, indicating short‑term financial strain.

Market effects

Highlights challenges for niche medical‑device firms reliant on single large customers.

Limited to U.S. small‑cap biotech/med‑tech segment.

Minimal beyond the company's niche market.

Counterpoint

If the new reimbursement codes drive higher utilization, the stock could rebound despite the near‑term miss.

Key entities

  • Joseph Sardano

    Chairman and CEO who commented on the results.

Related articles

$SRTSMed

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

Sensus Healthcare, Inc. (SRTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase

$AGROHighAI 8/10

Adecoagro (AGRO) Q3 2026 Earnings Call Transcript

Adecoagro reported Q3 2026 earnings, with gross sales of $591M and year-to-date sales of $1.5B. Fertilizers drove growth, offsetting lower Sugar, Ethanol, and Energy revenues. Adjusted EBITDA reached a 9-month high. The company acquired the Caarapó mill, expecting it to boost crushing volumes. Fertilizers and Food/Agriculture segments performed strongly, while Sugar/Ethanol faced cost pressures and lower sales.

$FIGRHighAI 8/10

Figure Tech (FIGR) Q3 2026 Earnings Call Transcript

Figure Tech (FIGR) reported Q3 2026 earnings with $5.8B volume, up 107% YoY, and 58% EBITDA margin. The company processed $5.1B organically and $0.7B from Kiavi. Figure Connect accounted for 72% of volume. They added 612 partners, expanded SMB business to $500M run rate, and launched new AI-driven products. Kiavi acquisition added $8B volume and new asset classes, expected to be accretive. The company saw resilience in higher interest rates, with strong investor demand and securitizations.

$CDNLMedAI 8/10

Cardinal Infra (CDNL) Q3 2026 Earnings Call Transcript

Cardinal Infra (CDNL) reported Q3 2026 revenue of $202M, up 65%, but adjusted EBITDA fell to $9M from $21M YoY. The company withdrew full-year guidance due to project estimate revisions and operational challenges. The board authorized a $50M share repurchase program. CFO Mike Rowe will step down, and the company is focusing on improving execution and profitability.